Literature DB >> 25989477

Factors impeding the discovery of an intervention-based treatment for type 1 diabetes.

M G von Herrath1,2, O Korsgren3, M A Atkinson4.   

Abstract

Type 1 diabetes (T1D) is one of the most common and severe chronic diseases affecting both children and adults. The aetiology of the disease remains unknown, and thus far no 'true' cure for those affected is available. Indeed, exogenous insulin replacement therapy to manage glucose metabolism to the best degree possible remains the current standard of care. However, despite a recent array of truly impressive improvements designed to enhance disease management (e.g. insulin analogues, continuous glucose monitoring, insulin pumps), it is still difficult for the vast majority of patients to reach recommended target HbA1C levels (< 7.0%). As a result of suboptimal disease management, far too many patients with T1D have an increased risk for disease-associated complications such as nephropathy, neuropathy and retinopathy, as well as hypoglycaemia. New treatment modalities are therefore needed urgently to bring a 'true' cure (disease prevention/disease reversal) to patients with T1D. Here we consider issues that collectively pose a major stumbling block in T1D research with respect to identifying a means to prevent and/or cure the disease. We begin this Perspective by discussing new insights emanating from studies of the pancreas in human T1D; findings which may, at least in part, explain why previous interventions seeking disease prevention/reversal have yielded insufficient benefit. We then turn to suggestions that could optimise the outcome of future clinical trials. Finally, we direct attention to recommendations for the global T1D research community; messages we deem to have the potential to improve our chances of finding the elusive T1D 'cure'.
© 2015 British Society for Immunology.

Entities:  

Keywords:  autoimmune disease; beta cells; immune therapy; insulin; type 1 diabetes

Mesh:

Substances:

Year:  2015        PMID: 25989477      PMCID: PMC4687509          DOI: 10.1111/cei.12656

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

Review 1.  Genetic protection from the inflammatory disease type 1 diabetes in humans and animal models.

Authors:  J A Todd; L S Wicker
Journal:  Immunity       Date:  2001-09       Impact factor: 31.745

2.  Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood.

Authors:  Jacqueline D Trudeau; Carolyn Kelly-Smith; C Bruce Verchere; John F Elliott; Jan P Dutz; Diane T Finegood; Pere Santamaria; Rusung Tan
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

3.  Immunosuppressive drugs and the risk of cancer after organ transplantation.

Authors:  Jacques Dantal; Jean-Paul Soulillou
Journal:  N Engl J Med       Date:  2005-03-31       Impact factor: 91.245

4.  Pathologic anatomy of the pancreas in juvenile diabetes mellitus.

Authors:  W Gepts
Journal:  Diabetes       Date:  1965-10       Impact factor: 9.461

5.  Expression of human leukocyte antigen class I in endocrine and exocrine pancreatic tissue at onset of type 1 diabetes.

Authors:  Oskar Skog; Stella Korsgren; Anna Wiberg; Angelika Danielsson; Bjørn Edwin; Trond Buanes; Lars Krogvold; Olle Korsgren; Knut Dahl-Jørgensen
Journal:  Am J Pathol       Date:  2015-01       Impact factor: 4.307

6.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Authors:  Bart Keymeulen; Evy Vandemeulebroucke; Anette G Ziegler; Chantal Mathieu; Leonard Kaufman; Geoff Hale; Frans Gorus; Michel Goldman; Markus Walter; Sophie Candon; Liliane Schandene; Laurent Crenier; Christophe De Block; Jean-Marie Seigneurin; Pieter De Pauw; Denis Pierard; Ilse Weets; Peppy Rebello; Pru Bird; Eleanor Berrie; Mark Frewin; Herman Waldmann; Jean-François Bach; Daniel Pipeleers; Lucienne Chatenoud
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

7.  Insulin autoimmunity: immunogenetics/immunopathogenesis of type 1A diabetes.

Authors:  George S Eisenbarth
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

8.  In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis.

Authors:  G F Bottazzo; B M Dean; J M McNally; E H MacKay; P G Swift; D R Gamble
Journal:  N Engl J Med       Date:  1985-08-08       Impact factor: 91.245

Review 9.  Update on worldwide efforts to prevent type 1 diabetes.

Authors:  Jay S Skyler
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

10.  Aberrant expression of class II major histocompatibility complex molecules by B cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in type 1 (insulin-dependent) diabetes mellitus.

Authors:  A K Foulis; M A Farquharson; R Hardman
Journal:  Diabetologia       Date:  1987-05       Impact factor: 10.122

View more
  10 in total

1.  Relative Pancreas Volume Is Reduced in First-Degree Relatives of Patients With Type 1 Diabetes.

Authors:  Martha L Campbell-Thompson; Stephanie L Filipp; Joseph R Grajo; Bimota Nambam; Richard Beegle; Erik H Middlebrooks; Matthew J Gurka; Mark A Atkinson; Desmond A Schatz; Michael J Haller
Journal:  Diabetes Care       Date:  2018-12-14       Impact factor: 19.112

2.  Alpha-1 Antitrypsin Therapy for Autoimmune Disorders.

Authors:  Sihong Song
Journal:  Chronic Obstr Pulm Dis       Date:  2018-10-05

3.  PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes.

Authors:  Moufida Ben Nasr; Sara Tezza; Francesca D'Addio; Chiara Mameli; Vera Usuelli; Anna Maestroni; Domenico Corradi; Silvana Belletti; Luca Albarello; Gabriella Becchi; Gian Paolo Fadini; Christian Schuetz; James Markmann; Clive Wasserfall; Leonard Zon; Gian Vincenzo Zuccotti; Paolo Fiorina
Journal:  Sci Transl Med       Date:  2017-11-15       Impact factor: 17.956

4.  Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production.

Authors:  Ariana Barbera Betancourt; Juliet L Emery; Asha Recino; F Susan Wong; Anne Cooke; Klaus Okkenhaug; Maja Wallberg
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

5.  Reply to "Tolerogenic insulin peptide therapy precipitates type 1 diabetes".

Authors:  Carolin Daniel; Benno Weigmann; Harald von Boehmer
Journal:  J Exp Med       Date:  2017-05-23       Impact factor: 14.307

Review 6.  Type 1 Diabetes Mellitus in Saudi Arabia: A Soaring Epidemic.

Authors:  Asirvatham Alwin Robert; Abdulrahman Al-Dawish; Muhammad Mujammami; Mohamed Abdulaziz Al Dawish
Journal:  Int J Pediatr       Date:  2018-05-08

7.  NK Cell Subsets Changes in Partial Remission and Early Stages of Pediatric Type 1 Diabetes.

Authors:  Laia Gomez-Muñoz; David Perna-Barrull; Adrian Villalba; Silvia Rodriguez-Fernandez; Rosa-Maria Ampudia; Aina Teniente-Serra; Federico Vazquez; Marta Murillo; Jacobo Perez; Raquel Corripio; Joan Bel; Marta Vives-Pi
Journal:  Front Immunol       Date:  2021-01-25       Impact factor: 7.561

Review 8.  Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes.

Authors:  Minh N Pham; Matthias G von Herrath; Jose Luis Vela
Journal:  Front Immunol       Date:  2016-01-11       Impact factor: 7.561

9.  Skin-Related Complications Among Adolescents With Type 1 Diabetes Using Insulin Pump Therapy.

Authors:  Ayman A Al Hayek; Asirvatham A Robert; Mohamed A Al Dawish
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2018-09-05

10.  Immunomodulatory Dual-Sized Microparticle System Conditions Human Antigen Presenting Cells Into a Tolerogenic Phenotype In Vitro and Inhibits Type 1 Diabetes-Specific Autoreactive T Cell Responses.

Authors:  Maigan A Brusko; Joshua M Stewart; Amanda L Posgai; Clive H Wasserfall; Mark A Atkinson; Todd M Brusko; Benjamin G Keselowsky
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.